JJDC sources equity investments and utilizes relationships with the private venture community to support innovation and create options in areas of strategic interest to Johnson & Johnson.
JJDC is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.
JJDC invests in companies with technologies that we believe have the potential to make significant impact on patient health. With a focus on a diverse range of opportunities in pharmaceutical, biotech, medical device, diagnostic and Consumer healthcare investing, JJDC doesn’t believe in a one-size-fits-all approach. We understand that each idea is unique and requires equally distinct investment strategy. We customize each deal to fit the opportunity, ranging from Seed and Series A investments in earliest stage startups, to Series B and beyond in more mature companies.
At JJDC we strongly believe in Value-Add investing and play an active role in the companies we invest. We provide not only strategic direction, but also access to internal experts across the Johnson & Johnson Family of Companies who can provide counsel across a broad spectrum of areas, including technical, scientific, manufacturing, clinical and regulatory. This approach allows the companies in which we invest to leverage Johnson & Johnson’s broad and deep R&D and therapeutic area experience in order to maximize value creation.
JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.